THE CHOICE OF ANESTHETIC TYPE AND CONDITIONS FOR 2,3,5-TRIPHENYLTETRAZOLIUM CHLORIDE STAINING OF BRAIN SLICES IS IMPORTANT IN THE ASSESSMENT OF ISCHEMIC INJURY IN RATS IN THE EARLY STAGES OF PATHOLOGY

Bilan DS^{1,2}, Kelmanson IV¹, Belousov VV^{1,2} ✉

¹Laboratory for Molecular Technologies, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia

²Department of Brain-Computer Interfaces, Research Institute for Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Studies of ischemic brain injury are an important area of modern biomedical research. So far, a lot of ischemic stroke models have been proposed, along with different imaging and staining modalities aimed to visualize the damaged tissue. In this work we use a rat model to investigate how the experimental setup affects the interpretation of experimental data obtained in the acute phase of ischemic stroke (5 hours after the occlusion of the middle cerebral artery). We show the association between the choice of the type of anesthesia and the severity of ischemic injury: in our experiments brain damage was the most pronounced in the animals anesthetized with a combination of chloral hydrate and Rometar; the least damage was observed for isoflurane. Staining was performed using the popular dye 2,3,5-triphenyltetrazolium chloride (TTC). We demonstrate that parameters of brain slices incubation in TTC also need to be accounted for when interpreting the results obtained during the acute phase of stroke, the optimum incubation time being 30 min and temperature 37 °C.

Keywords: stroke, ischemic injury, brain slices, 2,3,5-triphenyltetrazolium chloride, staining, anesthesia, rats

Funding: this work was supported by the Russian Science Foundation (Grant 17-15-01175)

✉ **Correspondence should be addressed:** Vsevolod Belousov
ul. Miklukho-Maklaya, d. 16/10, Moscow, Russia, 117997; belousov@ibch.ru

Received: 29.11.2017 **Accepted:** 10.12.2017

ВЛИЯНИЕ ТИПА АНЕСТЕЗИИ И УСЛОВИЙ ПРОКРАШИВАНИЯ ТКАНЕЙ МОЗГА КРАСИТЕЛЕМ 2,3,5-ТРИФЕНИЛТЕТРАЗОЛИЕМ ХЛОРИСТЫМ (ТТХ) НА ОЦЕНКУ ИШЕМИЧЕСКОГО ПОВРЕЖДЕНИЯ МОЗГА КРЫС НА РАННИХ СТАДИЯХ ПАТОГЕНЕЗА

Д. С. Билан^{1,2}, И. В. Кельмансон¹, В. В. Белоусов^{1,2} ✉

¹Лаборатория молекулярных технологий, Институт биоорганической химии имени академиков М. М. Шемякина и Ю. А. Овчинникова РАН, Москва

²Отдел нейро-компьютерных интерфейсов, НИИ трансляционной медицины, Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва

Изучение ишемического повреждения головного мозга является важным направлением современных медико-биологических исследований. К настоящему моменту разработано множество моделей ишемического инсульта, а также предложены различные способы визуализации поврежденных тканей мозга. В данной работе мы исследовали, как различные условия проведения эксперимента, моделирующего ишемический инсульт у крыс, влияют на интерпретацию результатов в острой фазе заболевания (5 ч с момента окклюзии средней мозговой артерии крыс). Мы показали, что на ранней стадии развития патологии существенное влияние оказывает выбор используемой анестезии животных. В наибольшей степени повреждение мозга было выражено при использовании для анестезии смеси хлоралгидрат/Рометар, в наименьшей — при использовании изофлурана. Для визуализации повреждения мозга животных мы использовали наиболее популярный краситель 2,3,5-трифенилтетразолий хлористый (ТТХ). Мы установили, что температура и время инкубации срезов мозга в растворе ТТХ также значительно влияют на интерпретацию результатов при оценке ишемического повреждения в острой фазе патологии. Оптимальными условиями окрашивания срезов мозга в растворе ТТХ являются 30-минутная инкубация срезов при 37 °C.

Ключевые слова: инсульт, ишемическое повреждение, срезы мозга, 2,3,5-трифенилтетразолий хлористый, окрашивание, анестезия, крысы

Финансирование: работа выполнена при поддержке Российского научного фонда, грант № 17-15-01175

✉ **Для корреспонденции:** Белоусов Всеволод Вадимович
ул. Миклухо-Маклая, д. 16/10, г. Москва, 117997; belousov@ibch.ru

Статья получена: 29.11.2017 **Статья принята к печати:** 10.12.2017

Ischemic stroke is one of the most serious neurological conditions and the second leading cause of death and disabilities worldwide after cardiovascular diseases [1–4]. So far, no effective treatment strategies have been proposed for this disease, and its pathogenesis remains understudied.

Of all currently existing models of ischemic stroke [5–12], monofilament occlusion of the middle cerebral artery stands out as the most common. First described by Koizumi et al. [13], it has been improved and adapted for use in different laboratory animals, such as rats [14] and mice [15].

Along with the variety of ischemic stroke models, there are different techniques allowing visualization of stroke-induced tissue damage. Infarcted zones of brain sections can be made visible using histological stains, such as traditional hematoxylin and eosin [16, 17], or Nissl staining and its modifications [18, 19]. Impregnation of nervous tissue with silver is reported to be helpful in detecting neuronal degeneration in the early stages of stroke [20, 21]. The same is true for Fluoro-Jade stains [22–24], but the exact mechanism of their action is still unknown. One of the simplest techniques to visualize ischemic lesions in brain slices is 2,3,5-triphenyltetrazolium chloride (TTC) staining [25]. Enzymes with dehydrogenase activity found in living cells reduce TTC to formazan, which stains healthy tissue deep red, whereas damaged tissue lacking healthy mitochondrial activity resists staining. Immunohistochemistry also has something to offer and can be employed to observe apoptotic cells in the lesion [26, 27]. Non-invasive techniques for stroke diagnosis include magnetic resonance imaging [28], positron emission tomography [29] and single-photon emission computed tomography [30]. The list of approaches to ischemic injury visualization is not limited to these modalities; detailed information is available in themed reviews [31].

Because approaches to studying stroke pathogenesis and developing treatment strategies are so different, the Stroke Therapy Academic Industry Roundtable (STAIR) has prepared a series of guidelines on ischemic stroke modeling [32–35], describing, in particular, a number of factors affecting its results

and their interpretation, such as the selected model itself, the animal's breed, the type of an anesthetic, the visualization technique, etc.

Even protocols for standard interventions may vary greatly. For example, TTC staining, which is now the most common technique used to visualize ischemic areas in brain slices, was originally performed on rats' brain sections 24 hours after induced occlusion (the brain sections were incubated for 30 min at 37 °C) [25]. However, some authors were able to visualize infarcted tissue using TTC staining just a few hours after occlusion [21, 36–43]. Incubation time of brain slices in the TTC solution may vary from 5 min [44] to standard 30 min [25]. Some protocols warn that TTC is unstable when heated, therefore, staining should be performed at room temperature [45]. TTC is mainly used for staining brain slices, but sometimes animals are perfused with TTC transcardially [38, 46].

In this work we show that effective visualization of damaged tissue obtained from rats with acute ischemia depends largely on temperature and duration of incubation of brain slices in the TTC solution. These two factors can skew interpretation of the results. We also demonstrate that the type of an anesthetic affects the scope of ischemic injury in the early stage of stroke (5 hours after the occlusion), while in the later stages (24 hours after the occlusion) its role is insignificant.

METHODS

Experiments involving animals were carried out in compliance with the Directive 2010/63/EU of the European Parliament and the European Council, dated September 22, 2010. The study protocol was approved by the Animal Care and Use Committee of the Institute of Bioorganic Chemistry, RAS.

The study was carried out in male Wistar rats (weight ranging from 280 g to 330 g) purchased from Pushchino breeding facility. The rats were kept in the animal house of the Institute of Bioorganic Chemistry in plastic cages, 3 animals per cage. The animals had free access to water and food.

Fig. 1. Effects of different temperatures and duration of incubation of rat brain slices in 1 % TTC solution on visualization of ischemic injury 5 hours after the occlusion. The pictures show brain slices obtained from a Wistar rat with the occluded middle cerebral artery. One slice was stained at room temperature, another — at 37 °C. Samples were photographed at set time intervals. Anesthetic used: Zoletil/Rometa

Occlusion of the middle cerebral artery was induced according to the protocol [14]. We used three types of anesthetics:

1. isoflurane (marketed as Aerrane by Baxter, USA): a 5 % concentration for general anesthesia induction and a 1.5 % concentration for anesthesia maintenance.

2. tiletamine hydrochloride/zolazepam hydrochloride (Zoletil by Virbac Sante Animale, France; 40 mg/kg) + xylazine hydrochloride (Rometa by Bioveta, Czech Republic; 10 mg/kg), injected intraperitoneally;

3. chloral hydrate (Dia-M, Russia, 400 mg/kg).

The animals were analgesized with 5 mg/kg ketoprofen (Ketonal by Sandoz, Switzerland) administered subcutaneously; local analgesia was induced by administering 2 % Novocain.

In our study we used commercial middle cerebral artery sutures by Doccol (USA; catalog number 403756PK10Re) 0.185 mm in diameter.

The rats were decapitated after set time intervals, their brains removed and cut into 2 mm thick frontal sections, which were then placed in 1 % TTC solution (Sigma-Aldrich, USA). Staining was done at different temperatures (20 °C and 37 °C).

RESULTS

In an attempt to investigate how different TTC staining conditions affect visualization of ischemic lesions, we modeled middle cerebral artery occlusion in rats [14]. The occlusion was

permanent, i. e. the vessel remained blocked throughout the experiment. The animals were anesthetized with a mixture of Zoletil and Rometa injected intraperitoneally. Five hours after the occlusion the brains were removed and cut into 2 mm thick frontal sections. Then, some slices were incubated in 1 % TTC solution at room temperature, while other were placed into TTC preheated to 37 °C. Photos of brain sections were taken at equal time intervals to assess how different temperatures and duration of incubation in the TTC solution affected visualization of ischemic tissue. Lesions became visible after 10 min of incubation at both temperatures: unlike the intact areas, they were weakly stained (Fig. 1). Further incubation in TTC at 37 °C produced a more intense color; after 20 min of incubation the color contrast between the healthy and ischemic tissues became less pronounced, as the damaged tissue developed an intermediate pink color. However, at room temperature the color contrast between the damaged and healthy tissues increased. Longer incubation at 37 °C produced a well-developed color throughout ischemic areas (Fig. 1). It is very important to control TTC staining conditions when only a short time has elapsed after occlusion induction, because damaged tissue may still contain living cells affecting color development. Twenty-four hours after the occlusion, the injury was clearly visible, and the color contrast between the lesion and the healthy tissue did not lose its intensity even after 2 hours of incubation at 37 °C.

Our next step was to find out how a choice of an anesthetic influences the scope of ischemic brain injury. Damaged tissue was visualized using TTC staining. In this series of experiments

Fig. 2. Effects of different anesthetics on the scope of ischemic injury in rats with the permanently occluded middle cerebral artery (5 hours after the occlusion). Brain slices were incubated under identical conditions in 1 % TTC solution for 30 min at 37 °C

Fig. 3. Brain slices of rats anesthetized with different drugs 24 hours after the induced permanent occlusion of the middle cerebral artery. The slices were incubated under identical conditions in 1 % TTC solution for 30 min at 37 °C

we also modeled permanent middle cerebral artery occlusion in Wistar rats. The animals were anesthetized using three types of anesthetics: isoflurane (Aerrane), a mixture of Zoletil and Rometar injected intraperitoneally and a mixture of chloral hydrate and Rometar also injected intraperitoneally. Five hours after the occlusion the brains were removed, sectioned, and incubated in 1 % TTC solution at 37 °C for 30 min. The lesion size was the smallest in the animals who had received isoflurane (this was reliably demonstrated in 6 animals), and the color contrast between the damaged and healthy TTC-stained tissues was minimal. The most severe damage was observed in the animals who had received a mixture of chloral hydrate and Rometar (this was reliably demonstrated in 5 animals). The Rometar/Zoletil mix produced interesting results. Of 7 animals, only 2 developed massive stroke; in 5 other animals the lesions did not develop a contrasting color during staining (Fig. 2). To sum up, the choice of an anesthetic is an important factor that must be accounted for when studying acute ischemia. The underlying cause of the contributions made by anesthetics is not clear, though. The neuroprotective effect of isoflurane has been reported by a number of authors [47–49], but its mechanism remains unexplained. Interestingly, 24 hours after the occlusion of the middle cerebral artery in rats, the size of the lesion did not depend on the type of an anesthetic (Fig. 3).

DISCUSSION

We have analyzed how different factors affect the results of TTC staining of brain sections obtained from rats with induced permanent ischemia. Our study demonstrates that visualization of damaged tissue in the early phases of stroke (5 hours after the occlusion) is particularly sensitive to TTC staining conditions (incubation temperature and duration) and the type of an anesthetic. Therefore, we do not recommend TTC staining for assessing the size of the lesion in the early stages of ischemic stroke, regardless of the opinion expressed in a number of academic works.

Besides, TTC staining does not provide unambiguous evidence about the viability of cells in the ischemic tissue during the acute stage. TTC is an indicator of mitochondrial dehydrogenase activity. A number of studies confirm that mitochondrial dysfunction is one of the major consequences of ischemia [50, 51]. However, an intermediate color developed by tissue during staining raises a question of interpretation.

Normally, in healthy tissue TTC is enzymically reduced to formazan, which stains the tissue deep red. In dead tissue this reaction does not happen, and the tissue remains white. But in our experiments the ischemic tissue developed an intermediate pink color whose intensity was growing as the incubation time and temperature of the environment were increasing. In the study [52] the researchers calculated the proportion of intact mitochondria in the brain sections that were subject to TTC staining and developed or did not develop a color. The study showed that about 5 % of mitochondria were intact in the areas that did not stain. Intermediate pink meant that the proportion of functioning mitochondria in the lesion was higher.

It is known that permanent occlusion does not necessarily cause immediate damage to mitochondria, and the latter remain intact for a few hours or even days, while other cell organelles, such as the nucleus, have already been destroyed [52]. In this case TTC-based visualization will not show tissue damage and, therefore, the real picture of progressing pathology will be blurred. A more traumatizing ischemia-reperfusion injury causes more rapid damage to mitochondria, which also should be accounted for when working with certain stroke models. Besides, TTC staining is not recommended for longer than 24 hours following artery occlusion because the lesions can accumulate inflammatory cells with intact mitochondria [52].

CONCLUSIONS

Our study conducted in rats with the permanently occluded middle cerebral artery demonstrates that estimates of the ischemic injury size in the early stages of stroke are affected by a number of factors, including the type of an anesthetic and staining conditions. Five hours after the occlusion, the least damage was observed in rats anesthetized with isoflurane; the most severe damage was observed in the animals who had received the chloral hydrate/Rometar mix. The optimum conditions for TTC staining of brain slices are 30 min incubation at 37 °C. Protocols that recommend a shorter incubation time and lower temperatures can yield incorrect results for the samples obtained in the early stages of stroke. But 24 hours after the occlusion damaged areas can be effectively visualized using TTC staining, regardless of incubation time/temperature and the selected anesthetic. Therefore, 24 hours are optimal for qualitative and quantitative TTC-based analysis of ischemic brain injury.

References

1. who.int [Internet]. World Health Organisation WHO. The top 10 causes of death; c2016 [cited Jan 2012]. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>.
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2009; 119 (3): e21–181. DOI: 10.1161/CIRCULATIONAHA.108.191261.
3. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *Lancet Glob Health*. 2013 Nov; 1 (5): e259–81. DOI: 10.1016/S2214-109X(13)70089-5.
4. Stakhovskaia LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. [Epidemiology of stroke in the Russian Federation: results of territory's population registry]. *Zhurnal Nevrologii i Psikiatrii Im. S. S. Korsakova*. 2013; 113 (5): 4–10. Russian.
5. Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. *J Neurosurg*. 1987 Sep; 67 (3): 394–8. DOI: 10.3171/jns.1987.67.3.0394.
6. Busch E, Kruger K, Hossmann KA. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. *Brain Res*. 1997 Dec 5; 778 (1): 16–24.
7. Roos MW, Ericsson A, Berg M, Sperber GO, Sjoquist M, Meyerson BJ. Functional evaluation of cerebral microembolization in the rat. *Brain Res*. 2003 Jan 24; 961 (1): 15–21.
8. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol*. 1985 May; 17 (5): 497–504. DOI: 10.1002/ana.410170513.
9. Sharkey J, Ritchie IM, Kelly PA. Perivascular microapplication

- of endothelin-1: a new model of focal cerebral ischaemia in the rat. *J Cereb Blood Flow Metab.* 1993 Sep; 13 (5): 865–71. DOI: 10.1038/jcbfm.1993.108.
10. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. *J Cereb Blood Flow Metab.* 1981; 1 (1): 53–60. DOI: 10.1038/jcbfm.1981.6.
 11. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. *Pharmacol Biochem Behav.* 2007 May; 87 (1): 179–97. DOI: 10.1016/j.pbb.2007.04.015.
 12. Fluri F, Schuhmann MK, Kleinschmitt C. Animal models of ischemic stroke and their application in clinical research. *Drug Des Devel Ther.* 2015 Jul 2; 9: 3445–54. DOI: 10.2147/DDDT.S56071.
 13. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G. Experimental studies of ischemic brain edema: 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. *Jpn Stroke J.* 1986; 8: 1–8.
 14. Uluc K, Miranpuri A, Kujoth GC, Akture E, Baskaya MK. Focal cerebral ischemia model by endovascular suture occlusion of the middle cerebral artery in the rat. *J Vis Exp.* 2011 Feb 5; (48). pii: 1978. DOI: 10.3791/1978.
 15. Engel O, Kolodziej S, Dirnagl U, Prinz V. Modeling stroke in mice - middle cerebral artery occlusion with the filament model. *J Vis Exp.* 2011 Jan 6; (47). pii: 2423. DOI: 10.3791/2423.
 16. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. *Am J Pathol.* 1993 Feb; 142 (2): 623–35.
 17. Zhang RL, Chopp M, Jiang N, Tang WX, Probst J, Manning AM et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. *Stroke.* 1995 Aug; 26 (8): 1438–42; discussion 1443.
 18. Li H, Zhang N, Lin HY, Yu Y, Cai QY, Ma L et al. Histological, cellular and behavioral assessments of stroke outcomes after photothrombosis-induced ischemia in adult mice. *BMC Neurosci.* 2014 May 2; 15: 58. DOI: 10.1186/1471-2202-15-58.
 19. Rousset E, Kriz J, Seidah NG. Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. *J Vis Exp.* 2012; (69). pii: 4038. DOI: 10.3791/4038.
 20. de Olmos JS, Beltramino CA, de Olmos de Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. *Neurotoxicol Teratol.* 1994 Nov-Dec; 16 (6): 545–61.
 21. Vogel J, Mobius C, Kuschinsky W. Early delineation of ischemic tissue in rat brain cryosections by high-contrast staining. *Stroke.* 1999 May; 30 (5): 1134–41.
 22. Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. *Brain Res.* 1997 Mar 14; 751 (1): 37–46.
 23. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. *Brain Res.* 2000 Aug 25; 874 (2): 123–30.
 24. Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. *Brain Res.* 2005 Feb 21; 1035 (1): 24–31. DOI: 10.1016/j.brainres.2004.11.054.
 25. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. *Stroke.* 1986 Nov-Dec; 17 (6): 1304–8.
 26. Linnik MD, Miller JA, Sprinkle-Cavallo J, Mason PJ, Thompson FY, Montgomery LR et al. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. *Brain Res Mol Brain Res.* 1995; 32 (1): 116–24. DOI: 10.1016/0169-328X(95)00069-5.
 27. Xu XH, Zhang SM, Yan WM, Li XR, Zhang HY, Zheng XX. Development of cerebral infarction, apoptotic cell death and expression of X-chromosome-linked inhibitor of apoptosis protein following focal cerebral ischemia in rats. *Life Sci.* 2006 Jan 11; 78 (7): 704–12. DOI: 10.1016/j.lfs.2005.05.080.
 28. Doyle FH, Pennock JM, Orr JS, Gore JC, Bydder GM, Steiner RE, et al. Imaging of the brain by nuclear magnetic resonance. *Lancet.* 1981; 2 (8237): 53–7.
 29. Kuhl DE, Phelps ME, Kowell AP, Metter EJ, Selin C, Winter J. Effects of stroke on local cerebral metabolism and perfusion: mapping by emission computed tomography of 18FDG and 13NH3. *Ann Neurol.* 1980; 8 (1): 47–60.
 30. Lassen NA, Henriksen L, Paulson O. Regional cerebral blood flow in stroke by 133Xenon inhalation and emission tomography. *Stroke.* 1981; 12 (3): 284–8.
 31. Zille M, Farr TD, Przesdzin I, Muller J, Sommer C, Dirnagl U et al. Visualizing cell death in experimental focal cerebral ischemia: promises, problems, and perspectives. *J Cereb Blood Flow Metab.* 2012 Feb; 32 (2): 213–31. DOI: 10.1038/jcbfm.2011.150.
 32. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent Stroke Model Guidelines for Preclinical Stroke Trials (1st Edition). *J Exp Stroke Transl Med.* 2009 Jan 1; 2 (2): 2–27.
 33. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. *Stroke.* 2001 Jul; 32 (7): 1598–606.
 34. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. *Stroke.* 2005; 36 (8): 1808–13.
 35. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke.* 2009 Jun; 40 (6): 2244–50. DOI: 10.1161/STROKEAHA.108.541128.
 36. Popp A, Jaenisch N, Witte OW, Frahm C. Identification of ischemic regions in a rat model of stroke. *PLoS One.* 2009; 4 (3): e4764. DOI: 10.1371/journal.pone.0004764.
 37. Liu F, Schafer DP, McCullough LD. TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. *J Neurosci Methods.* 2009 Apr 30; 179 (1): 1–8. DOI: 10.1016/j.jneumeth.2008.12.028.
 38. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, Harsing LG et al. Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. *Brain Res.* 2006 Oct 20; 1116 (1): 159–65. DOI: 10.1016/j.brainres.2006.07.123.
 39. Jiang LJ, Zhang SM, Li CW, Tang JY, Che FY, Lu YC. Roles of the Nrf2/HO-1 pathway in the anti-oxidative stress response to ischemia-reperfusion brain injury in rats. *Eur Rev Med Pharmacol Sci.* 2017 Apr; 21 (7): 1532–40.
 40. Si J, Chen L, Xia Z. Effects of cervical-lymphatic blockade on brain edema and infarction volume in cerebral ischemic rats. *Chin J Physiol.* 2006 Oct 31; 49 (5): 258–65.
 41. Deng YH, He HY, Yang LQ, Zhang PY. Dynamic changes in neuronal autophagy and apoptosis in the ischemic penumbra following permanent ischemic stroke. *Neural Regen Res.* 2016 Jul; 11 (7): 1108–14. DOI: 10.4103/1673-5374.
 42. Morris GP, Wright AL, Tan RP, Gladbach A, Ittner LM, Vissel B. A Comparative study of variables influencing ischemic injury in the longa and Koizumi methods of intraluminal filament middle cerebral artery occlusion in mice. *PLoS One.* 2016 Feb 12; 11 (2): e0148503. DOI: 10.1371/journal.pone.0148503.
 43. Park HS, Han KH, Shin JA, Park JH, Song KY, Kim DH. The neuroprotective effects of carnosine in early stage of focal ischemia rodent model. *J Korean Neurosurg Soc.* 2014 Mar; 55 (3): 125–30. DOI: 10.3340/jkns.2014.55.3.125.
 44. Matsuda F, Sakakima H, Yoshida Y. The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats. *Acta Physiol (Oxf).* 2011 Feb; 201 (2): 275–87. DOI: 10.1111/j.1748-1708.2010.02174.x.
 45. Chiang T, Messing RO, Chou WH. Mouse model of middle cerebral artery occlusion. *J Vis Exp.* 2011 Feb 13; (48). pii: 2761. DOI: 10.3791/2761.
 46. Dettmers C, Hartmann A, Rommel T, Kramer S, Pappata S, Young A, et al. Immersion and perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) compared to mitochondrial enzymes 6 hours after MCA-occlusion in primates.

- Neurol Res. 1994; 16 (3): 205–8.
47. Zheng S, Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. *Mol Pharmacol*. 2004 May; 65 (5): 1172–80. DOI: 10.1124/mo.65.5.1172.
 48. Chen F, Long Z, Yin J, Zuo Z, Li H. Isoflurane post-treatment improves outcome after an embolic stroke in rabbits. *PLoS One*. 2015; 10 (12): e0143931. DOI: 10.1371/journal.pone.0143931.
 49. Sun M, Deng B, Zhao X, Gao C, Yang L, Zhao H et al. Isoflurane preconditioning provides neuroprotection against stroke by regulating the expression of the TLR4 signalling pathway to alleviate microglial activation. *Sci Rep*. 2015 Jun 18; 5: 11445. DOI: 10.1038/srep11445.
 50. Christophe M, Nicolas S. Mitochondria: a target for neuroprotective interventions in cerebral ischemia-reperfusion. *Curr Pharm Des*. 2006; 12 (6): 739–57.
 51. Solenski NJ, diPierro CG, Trimmer PA, Kwan AL, Helm GA. Ultrastructural changes of neuronal mitochondria after transient and permanent cerebral ischemia. *Stroke*. 2002 Mar; 33 (3): 816–24.
 52. Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, et al. Limitations of tetrazolium salts in delineating infarcted brain. *Acta Neuropathol*. 1984; 65 (2): 150–7.

Литература

1. who.int [Internet]. World Health Organisation WHO. The top 10 causes of death; c2016 [cited Jan 2012]. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>.
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2009; 119 (3): e21–181. DOI: 10.1161/CIRCULATIONAHA.108.191261.
3. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *Lancet Glob Health*. 2013 Nov; 1 (5): e259–81. DOI: 10.1016/S2214-109X(13)70089-5.
4. Стаховская Л. В., Ключихина О. А., Богатырева М. Д., Коваленко В. В. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009–2010). *Журнал невропатологии и психиатрии им. С. С. Корсакова*. 2013; 113 (5): 4–10.
5. Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. *J Neurosurg*. 1987 Sep; 67 (3): 394–8. DOI: 10.3171/jns.1987.67.3.0394.
6. Busch E, Kruger K, Hossmann KA. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. *Brain Res*. 1997 Dec 5; 778 (1): 16–24.
7. Roos MW, Ericsson A, Berg M, Sperber GO, Sjoquist M, Meyerson BJ. Functional evaluation of cerebral microembolization in the rat. *Brain Res*. 2003 Jan 24; 961 (1): 15–21.
8. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol*. 1985 May; 17 (5): 497–504. DOI: 10.1002/ana.410170513.
9. Sharkey J, Ritchie IM, Kelly PA. Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat. *J Cereb Blood Flow Metab*. 1993 Sep; 13 (5): 865–71. DOI: 10.1038/jcbfm.1993.108.
10. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. *J Cereb Blood Flow Metab*. 1981; 1 (1): 53–60. DOI: 10.1038/jcbfm.1981.6.
11. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. *Pharmacol Biochem Behav*. 2007 May; 87 (1): 179–97. DOI: 10.1016/j.pbb.2007.04.015.
12. Fluri F, Schuhmann MK, Kleinschmitt C. Animal models of ischemic stroke and their application in clinical research. *Drug Des Devel Ther*. 2015 Jul 2; 9: 3445–54. DOI: 10.2147/DDDT.S56071.
13. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G. Experimental studies of ischemic brain edema: 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. *Jpn Stroke J*. 1986; 8: 1–8.
14. Uluc K, Miranpuri A, Kujoth GC, Akture E, Baskaya MK. Focal cerebral ischemia model by endovascular suture occlusion of the middle cerebral artery in the rat. *J Vis Exp*. 2011 Feb 5; (48). pii: 1978. DOI: 10.3791/1978.
15. Engel O, Kolodziej S, Dirnagl U, Prinz V. Modeling stroke in mice - middle cerebral artery occlusion with the filament model. *J Vis Exp*. 2011 Jan 6; (47). pii: 2423. DOI: 10.3791/2423.
16. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. *Am J Pathol*. 1993 Feb; 142 (2): 623–35.
17. Zhang RL, Chopp M, Jiang N, Tang WX, Probst J, Manning AM et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. *Stroke*. 1995 Aug; 26 (8): 1438–42; discussion 1443.
18. Li H, Zhang N, Lin HY, Yu Y, Cai QY, Ma L et al. Histological, cellular and behavioral assessments of stroke outcomes after photothrombosis-induced ischemia in adult mice. *BMC Neurosci*. 2014 May 2; 15: 58. DOI: 10.1186/1471-2202-15-58.
19. Rousselet E, Kriz J, Seidah NG. Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. *J Vis Exp*. 2012; (69). pii: 4038. DOI: 10.3791/4038.
20. de Olmos JS, Beltramino CA, de Olmos de Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. *Neurotoxicol Teratol*. 1994 Nov-Dec; 16 (6): 545–61.
21. Vogel J, Mobius C, Kuschinsky W. Early delineation of ischemic tissue in rat brain cryosections by high-contrast staining. *Stroke*. 1999 May; 30 (5): 1134–41.
22. Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. *Brain Res*. 1997 Mar 14; 751 (1): 37–46.
23. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. *Brain Res*. 2000 Aug 25; 874 (2): 123–30.
24. Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. *Brain Res*. 2005 Feb 21; 1035 (1): 24–31. DOI: 10.1016/j.brainres.2004.11.054.
25. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. *Stroke*. 1986 Nov-Dec; 17 (6): 1304–8.
26. Linnik MD, Miller JA, Sprinkle-Cavallo J, Mason PJ, Thompson FY, Montgomery LR et al. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. *Brain Res Mol Brain Res*. 1995; 32 (1): 116–24. DOI: 10.1016/0169-328X(95)00069-5.
27. Xu XH, Zhang SM, Yan WM, Li XR, Zhang HY, Zheng XX. Development of cerebral infarction, apoptotic cell death and expression of X-chromosome-linked inhibitor of apoptosis protein following focal cerebral ischemia in rats. *Life Sci*. 2006 Jan 11; 78 (7): 704–12. DOI: 10.1016/j.lfs.2005.05.080.

28. Doyle FH, Pennock JM, Orr JS, Gore JC, Bydder GM, Steiner RE, et al. Imaging of the brain by nuclear magnetic resonance. *Lancet*. 1981; 2 (8237): 53–7.
29. Kuhl DE, Phelps ME, Kowell AP, Metter EJ, Selin C, Winter J. Effects of stroke on local cerebral metabolism and perfusion: mapping by emission computed tomography of 18FDG and 13NH3. *Ann Neurol*. 1980; 8 (1): 47–60.
30. Lassen NA, Henriksen L, Paulson O. Regional cerebral blood flow in stroke by 133Xenon inhalation and emission tomography. *Stroke*. 1981; 12 (3): 284–8.
31. Zille M, Farr TD, Przesdzin I, Muller J, Sommer C, Dirnagl U et al. Visualizing cell death in experimental focal cerebral ischemia: promises, problems, and perspectives. *J Cereb Blood Flow Metab*. 2012 Feb; 32 (2): 213–31. DOI: 10.1038/jcbfm.2011.150.
32. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent Stroke Model Guidelines for Preclinical Stroke Trials (1st Edition). *J Exp Stroke Transl Med*. 2009 Jan 1; 2 (2): 2–27.
33. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. *Stroke*. 2001 Jul; 32 (7): 1598–606.
34. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. *Stroke*. 2005; 36 (8): 1808–13.
35. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke*. 2009 Jun; 40 (6): 2244–50. DOI: 10.1161/STROKEAHA.108.541128.
36. Popp A, Jaenisch N, Witte OW, Frahm C. Identification of ischemic regions in a rat model of stroke. *PLoS One*. 2009; 4 (3): e4764. DOI: 10.1371/journal.pone.0004764.
37. Liu F, Schafer DP, McCullough LD. TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. *J Neurosci Methods*. 2009 Apr 30; 179 (1): 1–8. DOI: 10.1016/j.jneumeth.2008.12.028.
38. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, Harsing LG et al. Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. *Brain Res*. 2006 Oct 20; 1116 (1): 159–65. DOI: 10.1016/j.brainres.2006.07.123.
39. Jiang LJ, Zhang SM, Li CW, Tang JY, Che FY, Lu YC. Roles of the Nrf2/HO-1 pathway in the anti-oxidative stress response to ischemia-reperfusion brain injury in rats. *Eur Rev Med Pharmacol Sci*. 2017 Apr; 21 (7): 1532–40.
40. Si J, Chen L, Xia Z. Effects of cervical-lymphatic blockade on brain edema and infarction volume in cerebral ischemic rats. *Chin J Physiol*. 2006 Oct 31; 49 (5): 258–65.
41. Deng YH, He HY, Yang LQ, Zhang PY. Dynamic changes in neuronal autophagy and apoptosis in the ischemic penumbra following permanent ischemic stroke. *Neural Regen Res*. 2016 Jul; 11 (7): 1108–14. DOI: 10.4103/1673-5374.
42. Morris GP, Wright AL, Tan RP, Gladbach A, Ittner LM, Vissel B. A Comparative study of variables influencing ischemic injury in the longa and Koizumi methods of intraluminal filament middle cerebral artery occlusion in mice. *PLoS One*. 2016 Feb 12; 11 (2): e0148503. DOI: 10.1371/journal.pone.0148503.
43. Park HS, Han KH, Shin JA, Park JH, Song KY, Kim DH. The neuroprotective effects of carnosine in early stage of focal ischemia rodent model. *J Korean Neurosurg Soc*. 2014 Mar; 55 (3): 125–30. DOI: 10.3340/jkns.2014.55.3.125.
44. Matsuda F, Sakakima H, Yoshida Y. The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats. *Acta Physiol (Oxf)*. 2011 Feb; 201 (2): 275–87. DOI: 10.1111/j.1748-1708.2010.02174.x.
45. Chiang T, Messing RO, Chou WH. Mouse model of middle cerebral artery occlusion. *J Vis Exp*. 2011 Feb 13; (48). pii: 2761. DOI: 10.3791/2761.
46. Dettmers C, Hartmann A, Rommel T, Kramer S, Pappata S, Young A, et al. Immersion and perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) compared to mitochondrial enzymes 6 hours after MCA-occlusion in primates. *Neurol Res*. 1994; 16 (3): 205–8.
47. Zheng S, Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. *Mol Pharmacol*. 2004 May; 65 (5): 1172–80. DOI: 10.1124/mo.65.5.1172.
48. Chen F, Long Z, Yin J, Zuo Z, Li H. Isoflurane post-treatment improves outcome after an embolic stroke in rabbits. *PLoS One*. 2015; 10 (12): e0143931. DOI: 10.1371/journal.pone.0143931.
49. Sun M, Deng B, Zhao X, Gao C, Yang L, Zhao H et al. Isoflurane preconditioning provides neuroprotection against stroke by regulating the expression of the TLR4 signalling pathway to alleviate microglial activation. *Sci Rep*. 2015 Jun 18; 5: 11445. DOI: 10.1038/srep11445.
50. Christophe M, Nicolas S. Mitochondria: a target for neuroprotective interventions in cerebral ischemia-reperfusion. *Curr Pharm Des*. 2006; 12 (6): 739–57.
51. Solenski NJ, diPierro CG, Trimmer PA, Kwan AL, Helm GA. Ultrastructural changes of neuronal mitochondria after transient and permanent cerebral ischemia. *Stroke*. 2002 Mar; 33 (3): 816–24.
52. Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, et al. Limitations of tetrazolium salts in delineating infarcted brain. *Acta Neuropathol*. 1984; 65 (2): 150–7.